(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2013 (31.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/163258 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61P 13/12* (2006.01)
A61K 31/712 (2006.01) *A61P 43/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2013/037913

(22) International Filing Date:
24 April 2013 (24.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/741,783	25 April 2012 (25.04.2012)	US
61/717,927	24 October 2012 (24.10.2012)	US
61/779,913	13 March 2013 (13.03.2013)	US

(71) Applicant: **REGULUS THERAPEUTICS INC.** [US/US]; 3545 John Hopkins Court, Suite 210, San Diego, California 92121 (US).

(72) Inventors; and
(71) Applicants : **BHAT, Balkrishen** [IN/US]; 3545 John Hopkins Court, Suite 210, San Diego, California 92121 (US). **MARCUSSON, Eric** [US/US]; 3545 John Hopkins Court, Suite 210, San Diego, California 92121 (US).

(74) Agent: **SCARR, Rebecca B.**; 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY

(57) **Abstract**: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

WO 2013/163258 A1